Pear Therapeutics Collaborates with Westwood & Wilshire to Place VP of Clinical Development

September 13, San Francisco, CA— Pear Therapeutics, a prescription digital therapeutics company, announced today that Maria Sullivan will be joining the company as Vice President of Clinical Development. The announcement comes off the news that Pear is taking a SPAC path to the Nasdaq. As the first company with FDA approvals in PDTs, Pear is valued at 1.6 billion and its advanced pipeline has a particular interest in CNS.

Dr. Sullivan is a leading expert in addiction medicine, and joins Pear from Alkermes where she was the Executive Medical Director for the Addiction unit. Before and throughout her six years at Alkermes, Dr. Sullivan served as an Associate Professor of Psychiatry at Columbia University, where she acted as principal investigator on several NIDA-backed clinical trials. She received her PhD from the University of Chicago and her MD from George Washington University.

This search was successfully led by Gerard Danishek for Westwood & Wilshire’s Life Sciences Practice. 

About Westwood & Wilshire

Westwood & Wilshire is a retained executive search firm that recognizes people as any organization’s top asset. The firm has delivered premier talent to many of the world’s most innovative companies in life sciences, healthcare, and advanced technology. Westwood & Wilshire specializes in bringing top-tier candidates at the mid-management to C-Suite level to clients ranging from VC backed start-ups to mid-sized commercial entities. The firm has offices in Los Angeles, Silicon Valley, Scottsdale, and Connecticut serving clients worldwide.